Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank
- 18 August 2025
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 43 (11) , 639-653
Abstract
No abstract availableKeywords
Funding Information
- Exelixis
This publication has 69 references indexed in Scilit:
- Using Effect Scores to Characterize Heterogeneity of Treatment EffectsJAMA, 2024
- Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020JAMA Network Open, 2024
- Causal Diagram Techniques for Urologic Oncology ResearchClinical Genitourinary Cancer, 2021
- Implications of the Revised Common Rule for Human Participant ResearchChest, 2019
- Randomization in Clinical TrialsJAMA, 2018
- Clinical trial designs incorporating predictive biomarkersCancer Treatment Reviews, 2016
- How to Use a Subgroup AnalysisJAMA, 2014
- Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypesHuman Genetics, 2011
- Limitations of Applying Summary Results of Clinical Trials to Individual PatientsJAMA, 2007
- MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORSStatistics in Medicine, 1996